Literature DB >> 31683469

Behaviour of carbonyl groups in several clinical conditions: Analysis of our survey.

Gregorio Caimi1, Eugenia Hopps1, Maria Montana1, Caterina Carollo1, Vincenzo Calandrino1, Eleonora Gallà1, Baldassare Canino1, Rosalia Lo Presti2.   

Abstract

Protein carbonylation is a marker of oxidative protein damage, that is likely involved in the pathogenesis of several diseases. The aim of this study was to evaluate the protein carbonyl (PC) groups in different clinical conditions. It included different groups of subjects: 81 trained subjects; 23 subjects with mild essential hypertension; 31 middle-aged subjects with metabolic syndrome (MS); 106 subjects with MS not selected for age (subdivided into two subgroups, with and without diabetes mellitus); 91 obese adults subdivided in two subgroups (BMI 30-35 Kg/m2 and BMI > 35 kg/m2); 48 subjects with obstructive sleep apnea syndrome (OSAS) subdivided in accordance with the apnea/hypopnea index (AHI); 27 subjects with chronic kidney disease (CKD) on conservative therapy; 31 subjects with CKD on haemodialysis treatment; and 50 subjects with juvenile myocardial infarction. PC groups were reduced in trained subjects in comparison with sedentary controls, while no variation was observed in mild essential hypertension. PC groups were increased in MS subjects and in adult obese subjects. In MS subjects the PC groups were not influenced by the presence of diabetes mellitus and in adult obese subjects were not influenced by the obesity degree. In OSAS subjects only those with AHI > 30 showed an increase of PC groups. PC groups increased in CKD subjects undergoing conservative treatment and haemodialysis therapy. In dialyzed subjects, after a standard dialysis session, there was a marked increase in PC groups. In juvenile myocardial infarction PC groups were higher than in controls; there was no difference between STEMI and NSTEMI and their concentration was unaffected by the number of cardiovascular risk factors or stenosed coronary vessels.

Entities:  

Keywords:  Oxidative stress, arterial hypertension, metabolic syndrome, juvenile myocardial zzm321990infarction, chronic kidney failure

Mesh:

Substances:

Year:  2020        PMID: 31683469     DOI: 10.3233/CH-190689

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  2 in total

1.  Clofibrate, a Peroxisome Proliferator-Activated Receptor-Alpha (PPARα) Agonist, and Its Molecular Mechanisms of Action against Sodium Fluoride-Induced Toxicity.

Authors:  Ademola Adetokunbo Oyagbemi; Olumuyiwa Abiola Adejumobi; Theophilus Aghogho Jarikre; Olumide Samuel Ajani; Ebunoluwa Racheal Asenuga; Idayat Titilayo Gbadamosi; Aduragbenro Deborah A Adedapo; Abimbola Obemisola Aro; Blessing Seun Ogunpolu; Fasilat Oluwakemi Hassan; Olufunke Olubunmi Falayi; Iyanuoluwa Omolola Ogunmiluyi; Temidayo Olutayo Omobowale; Oluwatosin Adetola Arojojoye; Olufunke Eunice Ola-Davies; Adebowale Benard Saba; Adeolu Alex Adedapo; Benjamin Obukowho Emikpe; Matthew Olugbenga Oyeyemi; Sanah Malomile Nkadimeng; Lyndy Joy McGaw; Prudence Ngalula Kayoka-Kabongo; Oluwafemi Omoniyi Oguntibeju; Momoh Audu Yakubu
Journal:  Biol Trace Elem Res       Date:  2021-04-24       Impact factor: 3.738

Review 2.  Plasma Protein Carbonyls as Biomarkers of Oxidative Stress in Chronic Kidney Disease, Dialysis, and Transplantation.

Authors:  Graziano Colombo; Francesco Reggiani; Claudio Angelini; Silvia Finazzi; Emanuela Astori; Maria L Garavaglia; Lucia Landoni; Nicola M Portinaro; Daniela Giustarini; Ranieri Rossi; Annalisa Santucci; Aldo Milzani; Salvatore Badalamenti; Isabella Dalle-Donne
Journal:  Oxid Med Cell Longev       Date:  2020-11-24       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.